Short Interest in Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Decreases By 84.7%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,800 shares, a decline of 84.7% from the October 15th total of 11,800 shares. Based on an average trading volume of 27,600 shares, the short-interest ratio is presently 0.1 days.

Scinai Immunotherapeutics Stock Performance

Shares of Scinai Immunotherapeutics stock traded down $0.08 during trading on Tuesday, hitting $3.03. 7,227 shares of the stock traded hands, compared to its average volume of 312,828. The company has a fifty day moving average price of $3.60 and a two-hundred day moving average price of $3.80. The stock has a market cap of $1.76 million, a P/E ratio of -0.01 and a beta of 2.46. Scinai Immunotherapeutics has a twelve month low of $2.23 and a twelve month high of $8.92.

Scinai Immunotherapeutics (NASDAQ:SCNI) last issued its earnings results on Thursday, August 15th. The company reported ($3.57) EPS for the quarter. The firm had revenue of $0.28 million during the quarter.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.